WuXi AppTec posts lower profits but avoids more share price pain
The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit Key Takeaways: U.S.…
2359.HK
603259.SHG
Recent Articles
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK
603259.SHG
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
BRIEF: WuXi AppTec sells advanced therapies units in U.K. and U.S.
2359.HK 603259.SHG
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
Discover hidden China stock gems in our weekly newsletter